Photocure ASA: Presentation of the second quarter 2016 results and Hexvix/Cysview update

Photocure will present its second quarter report on Tuesday 23 August 2016 at Hotel Continental, Oslo, Norway.

Additionally, Dr. Daneshmand will provide an update on Hexvix/Cysview following the new bladder cancer guidelines from American Urological Association (AUA) and the Society of Urological Oncology (SUO), where enhanced cystoscopy including Blue Light Cystoscopy with Hexvix/ Cysview is recommended.

Agenda (CET)

  • 08:30 - 09:05 Q2 presentation by Kjetil Hestdal, President and CEO, and Erik Dahl, CFO.
    The presentation will be held in Norwegian.
  • 09:05 - 09:15 Break
  • 09:15 - 09:45 Dr. Sia Daneshmand, MD, Associate Professor of Urology (Clinical Scholar); Director of Urologic Oncology, Director of Research and Fellowship Director, USC Institute of Urology at University of Southern California, Los Angeles, USA.
    The presentation will be held in English.
  • 09:45 - 10:00 Ambaw Bellete, President, Photocure Inc. and Head, US Commercial Operations.
    The presentation will be held in English.

A light snack will be served from 08:00.

The presentations will be publicly available at .

Photocure will additionally host an audio webcast and conference call ( ) the same day in English at 17:00 CET / 16:00 GMT / 12:00 EST.
Please join the event conference 5-10 minutes prior to the start time using the number and confirmation code below:

  • NORWAY:       +47 2100 2607
  • UK:                  +44(0)203 043 2002
  • USA:                +1 719 325 4936

 Confirmation code: 6357841
It is possible to listen to a replay of the conference call on the following numbers:

  • NORWAY         +47 2350 0077
  • UK                   +44 (0)207 984 7568
  • USA                 +1 719 457 0820

 Confirmation code: 6357841

Please register your attendance to the presentations at Photocure by Monday 22 August.
Contact person: Grete Faye-Schjøll (e-mail: / phone +47 22 06 22 10 / fax +47 22 06 22 18).

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Photocure ASA via GlobeNewswire